This article was originally published in The Gray Sheet
FDA's office of device evaluation considering creation of the new position. Modeled after the agency-level position, the ODE ombudsman would be charged with evaluating industry complaints about ODE activities.
You may also be interested in...
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.